Quadrivalent Influenza Vaccine Split Virion Inactivated High-Dose suspension for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) (2024)

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose, suspension for injection in pre-filled syringe

Quadrivalent influenza vaccine (split virion, inactivated), 60 micrograms HA/strain

Influenza virus (inactivated, split) of the following strains*:

A/Victoria/4897/2022 (H1N1)pdm09-like strain

(A/Victoria/4897/2022, IVR-238)… … … … … … … … … … … … … … … 60 micrograms HA**

A/Darwin/9/2021 (H3N2)-like strain

(A/Darwin/9/2021, SAN-010)… … … … … … … … … … … … … … … … … ..60 micrograms HA**

B/Austria/1359417/2021-like strain

(B/Michigan/01/2021, wild type)… … … … … … … … … … … … … … … 60 micrograms HA**

B/phu*ket/3073/2013-like strain

(B/phu*ket/3073/2013, wild type) … … … … … … … … … … … … … … 60 micrograms HA**

* propagated in embryonated chicken eggs

** haemagglutinin

This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2023/2024 season.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose may contain traces of eggs, such as ovalbumin, formaldehyde which are used during the manufacturing process (see Section 4.3).

For the full list of excipients, see Section 6.1.

Suspension for injection, in a pre-filled syringe

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose, after shaking gently, is a colourless opalescent liquid.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose is indicated for active immunisation in adults 60 years of age and older for the prevention of influenza disease.

The use of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose should be based in accordance with official recommendations on vaccination against influenza.

Posology

In adults 60 years of age and older: one dose of 0.7 ml.

Paediatric population

The safety and effectiveness of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose in children less than 18 years of age have not been established.

Method of administration

The preferred route of administration for this vaccine is intramuscular although it may also be given subcutaneously.

The recommended site for intramuscular injection is the deltoid region. The vaccine should not be injected into the gluteal region, or into areas where there may be a major nerve trunk.

For instructions on preparation of the medicinal product before administration, see Section 6.6.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose should under no circ*mstances be administered intravascularly.

Vaccination should be postponed in patients with acute febrile illness until the fever is resolved.

If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of any previous influenza vaccination, the decision to give Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose should be based on careful consideration of the potential benefits and risks.

As with other vaccines administered intramuscularly, the vaccine should be administered with caution to subjects with thrombocytopaenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.

As with any vaccine, a protective response may not be elicited in all vaccine recipients.

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “ sodium free” .

Co-administration of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose with an investigational booster 100 mcg dose of COVID-19 mRNA vaccine (nucleoside modified/elasomeran) has been evaluated in a limited number of participants in a descriptive clinical study (see sections 4.8 and 5.1).

If Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose needs to be given at the same time as another injectable vaccine(s), immunisation should be carried out on separate limbs.

It should be noted that the adverse reactions may be intensified by any co-administration.

The immunological response may be reduced if the patient is undergoing immunosuppressant treatment.

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been reported. An appropriate Western Blot test should be used to confirm or disprove the results of the ELISA test. The transient false positive reactions could be due to a non-specific IgM response induced by influenza vaccine.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose is only indicated for use in adults aged 60 years and older.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose has not been clinically evaluated in pregnant and breast-feeding women.

Pregnancy

Inactivated influenza standard dose vaccines (15 micrograms haemagglutinin of each virus strain per dose) can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester. Data from worldwide use of inactivated influenza standard dose vaccines do not indicate any adverse foetal and maternal outcomes attributable to the vaccine. However, data on the use of influenza vaccines containing 60 micrograms haemagglutinin of each virus strain per dose in pregnant women are limited.

Breastfeeding

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose may be used during breast-feeding. Based on experience with standard dose vaccines, no effects on the breast-fed infant are anticipated.

Fertility

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose has not been evaluated for possible effects on human fertility.

a. Summary of the safety profile

Adverse event information is based on data coming from two clinical trials with Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose and on the clinical and post-marketing experience of Trivalent Influenza Vaccine (Split Virion, Inactivated) High-Dose (TIV-HD).

The safety of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose was assessed in a pooled analysis of two clinical trials (QHD00013 and QHD00011) in which 2549 adults from 60 years of age and older (378 adults from 60 to 64 years of age and 2171 adults 65 years of age and older) received Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose.

The most frequently reported adverse reaction after vaccination was injection site pain reported by 42.6% of study participants followed by myalgia (23.8%), headache (17.3%) and malaise (15.6%). Most of these reactions occurred and resolved within three days of vaccination. The intensity of most of these reactions was mild to moderate.

Overall, adverse reactions were generally less frequent in participants aged 65 years and older than in participants aged 60 to 64 years.

Reactogenicity of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose was slightly increased as compared to the standard dose vaccine, but no major difference in intensity was observed.

The safety of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose (QIV-HD) was evaluated in a descriptive study (QHD00028) in which subjects received QIV-HD together with an investigational booster 100 mcg dose of COVID-19 mRNA vaccine (nucleoside modified) (n=100), QIV-HD only (n=92) or an investigational booster 100 mcg dose of COVID-19 mRNA vaccine (nucleoside modified) only (n=104). The frequency and severity of local and systemic adverse reactions was similar in subjects who were co-administered with QIV-HD and licensed COVID-19 mRNA vaccine and subjects administered with a booster dose of licensed COVID-19 mRNA vaccine.

b. Tabulated list of adverse reactions

The data below summarizes the frequencies of adverse reactions that were recorded following vaccination with Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose and adverse reactions reported during clinical development and post-marketing experience with TIV-HD (marked with * in the table below).

Adverse events are ranked under headings of frequency using the following convention:

Very common (≥ 1/10);

Common (≥ 1/100 to <1/10);

Uncommon (≥ 1/1,000 to <1/100);

Rare (≥ 1/10,000 to <1/1,000);

Very rare (<1/10,000);

Not known (cannot be estimated from available data).

^aDyspepsia, lethargy, and muscular weakness were observed with TIV-HD in the QHD00013 trial

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Medicines and Healthcare products Regulatory Agency (MHRA), Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02.

Annual influenza vaccination is recommended because immunity during the year after vaccination declines and because circulating strains of influenza virus change from year to year.

Pharmacodynamic effects

Immunogenicity - QHD00013

A randomized, active-controlled, modified double-blind Phase III clinical trial was conducted in the US in adults 65 years and older.

The objective was to demonstrate the noninferiority of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose over TIV-HD, as assessed by HAI (hemagglutinin inhibition) Geometric mean antibody titers (GMTs) at Day 28 and seroconversion rates.

A total of 2670 adults from 65 years of age were randomized to receive either one dose of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose or one dose of TIV-HD (one of two formulations of comparator vaccine [TIV-HD1 or TIV-HD2]); each TIV HD formulation contained a B strain that corresponds to one of the two B strains in Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose (either a B strain of the Yamagata lineage or a B strain of the Victoria lineage).

The immunogenicity results are summarized below in Table 1.

Table 1: Study 1a: Analyses of Noninferiority of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose Relative to TIV-HD by Post-Vaccination HAI Antibody GMTs and Seroconversion Rates in Adults 65 Years of Age and Older, Per-Protocol Analysis Set

^a NCT03282240

^b Seroconversion Rates: For subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥ 40 (1/dil) and for subjects with a pre-vaccination titer ≥ 10 (1/dil), proportion of subjects with a ≥ four-fold increase from pre- to post-vaccination titer.

^c N is the number of vaccinated participants with available data for the immunologic endpoint listed

^d TIV-HD1 contained A/Michigan/45/2015 (H1N1), A/Hong Kong/4801/2014 (H3N2), and B/Brisbane/60/2008 (B1, Victoria lineage).

^e TIV-HD2 contained A/Michigan/45/2015 (H1N1), A/Hong Kong/4801/2014 (H3N2), and B/phu*ket/3073/2013 (B2, Yamagata lineage).

^f Predefined noninferiority criterion for seroconversion rates: the lower limit of the two-sided 95% CI of the difference of the seroconversion rates (Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose minus TIV-HD) is >-10%. Predefined noninferiority criterion for the GMT ratio: the lower limit of the 95% CI of the GMT ratio (Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose divided by TIV-HD) is >0.667.

^g For the A strain comparison, TIV-HD1 and TIV-HD2 were pooled into a TIV-HD group for comparison with Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose was as immunogenic as TIV-HD for GMTs and seroconversion rates for the common influenza strains. Moreover, Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose induced a superior immune response with respect to the additional B strain than the immune response induced by TIV-HD that does not contain the corresponding B.

The efficacy and effectiveness results of TIV-HD are thus inferred to Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose given the demonstration of statistically comparable immunogenicity between TIV-HD and Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose.

QHD00011

A randomized, active-controlled, modified double-blind, Phase III clinical trial conducted in Europe in adults 60 years and older to demonstrate the superiority of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose over QIV-SD for all strains, as assessed by HAI (hemagglutinin inhibition) geometric mean antibody titers (GMTs) at Day 28 in adults 60 to 64 years of age and in adults 65 years of age and older.

A total of 1539 adults (760 adults 60 to 64 years of age and 779 adults 65 years of age and older) were randomized to receive either one dose of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose or one dose of QIV-SD.

Table 2: Study 2^a: Analyses of Superiority of Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose Relative to QIV-SD by Post-Vaccination HAI Antibody GMTs in Adults 60-64 Years of Age and 65 Years of Age and Older, Full Analysis Set

^a NCT04024228

^b N is the number of participants with available data for the considered endpoint

^c Superiority was concluded if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (QIV-HD/QIV-SD) was > 1 for each strain and in each age group

The efficacy and effectiveness results of TIV-HD are thus inferred to Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose, given the demonstration of statistically comparable immunogenicity between TIV-HD and Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose in adults 65 years of age and older (QHD00013) and similar immune responses observed in adults 60 to 64 years of age and in adults 65 years of age and older (QHD00011).

In addition, Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose induced an immune response that was superior to the responses induced by QIV-SD for all 4 virus strains 28 days post-vaccination in adults 60 to 64 years of age and in adults 65 years of age and older.

Pivotal Clinical Efficacy (FIM12)

FIM12 was a multi-centre, double-blind efficacy trial conducted in the US and Canada in which adults 65 years of age and older were randomised (1:1) to receive the TIV-HD or a standard dose vaccine. The study was conducted over two influenza seasons (2011-2012 and 2012-2013) to assess the occurrence of laboratory-confirmed influenza caused by any influenza viral type/subtype, in association with influenza-like illness (ILI) as the primary endpoint.

Participants were monitored for the occurrence of a respiratory illness by both active and passive surveillance, starting 2 weeks post-vaccination for approximately 7 months. After an episode of respiratory illness, nasopharyngeal swab samples were collected for analysis; attack rates and vaccine efficacy were calculated. The pre-specified statistical superiority criterion for the primary endpoint (lower limit of the 2-sided 95% CI of the vaccine efficacy for the TIV-HD relative to standard dose vaccine > 9.1%) was met.

Table3: Relative vaccine efficacy to prevent influenza-like illness^a in adults ≥ 65 years

^aOccurrence of at least one of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or difficulty breathing; concurrent with at least one of the following systemic signs or symptoms: temperature >37.2° C, chills, tiredness, headaches or myalgia

^bN is the number of vaccinated participants in the per-protocol analysis set for efficacy assessments

^cn is the number of participants with protocol-defined influenza-like illness with laboratory confirmation

^dLaboratory-confirmed: culture- or polymerase-chain-reaction-confirmed

^ePrimary endpoint

Effectiveness Studies

Randomized Clinical Trials

A cluster-randomized, controlled clinical trial in United States nursing homes assessed the relative effect of TIV-HD versus a standard dose of influenza vaccine in hospitalizations among 53008 individuals during the 2013-2014 influenza season.

During the 2013-2014 season, the incidence of respiratory-related hospital admissions (primary objective) was significantly reduced in facilities where residents received TIV-HD compared with those that received standard-dose influenza vaccines by 12.7% (adjusted risk ratio [ARR] 0.873, 95% CI 0.776 to 0.982, p=0.023). Moreover, with respect to secondary endpoints, TIV-HD reduced hospital admissions for pneumonia by 20.9% (ARR 0.791, 95% CI: 0.267 to 0.953, p=0.013) and all-cause hospital admissions by 8% (ARR 0.915, 95% CI: 0.863 to 0.970, p=0.0028).

Observational Studies

Several retrospective studies, over 8 influenza seasons and in more than 24 million individuals 65 years of age and older, confirmed the superior protection offered by TIV-HD compared to standard-dose influenza vaccines against complications of influenza such as pneumonia and influenza hospitalization (13.4% (95%CI: 7.3% to 19.2%, p<0.001)), cardio-respiratory hospitalizations 17.9% (95%CI :14.9% to 20.9%, p<0.001) and all – cause hospitalization 8.1% (95%CI: 5.9% to 10.3%, p<0.001) ; although the impact may vary per season.

Concomitant Administration with COVID-19 mRNA Vaccine (nucleoside modified)

In a descriptive open-label clinical study (NCT04969276), healthy adults aged 65 years and older were divided in three groups: Group 1 received Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose alone (N=92), Group 2 (N=100) received Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose concomitantly with an investigational booster 100 mcg dose of COVID-19 mRNA vaccine (nucleoside modified) at least 5 months after the second dose of the primary series, Group 3 (N=104) received only the investigational booster 100 mcg dose of COVID-19 mRNA vaccine (nucleoside modified) .

Co-administration resulted in no change to influenza vaccine immune responses as measured by hemagglutination inhibition (HAI) assay. Co-administration resulted in similar responses to COVID-19 mRNA vaccine, as assessed by an anti-spike IgG assay (see section 4.5 and 4.8).

Nonclinical data reveal no special hazards for humans based on conventional studies of local tolerance and repeated dose toxicity studies.

Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High‐ Dose has not been evaluated for carcinogenic or mutagenic potential nor for developmental and reproductive toxicity study.

• Sodium phosphate-buffered isotonic sodium chloride solution

• Octoxinol-9

0.7 ml of suspension in pre-filled syringe (Type I glass) equipped with a plunger stopper (bromobutyl rubber) and a tip-cap.

Pack of 1, 5 or 10 pre-filled syringe(s) without needle(s).

Pack of 1, 5 or 10 pre-filled syringe(s) with separate needle(s) (stainless steel).

Pack of 1 or 10 pre-filled syringe(s) with separate needle(s) (stainless steel) with safety shield (polycarbonate).

Not all pack sizes may be marketed.

The vaccine should be allowed to reach room temperature before use.

Shake before use.

The vaccines should be inspected visually for particulate matter and/or discoloration prior to administration whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

Preparation for Administration

The pre-filled syringe can be supplied with a Luer Lock with either Rigid Tip Cap (Picture A) or Soft Tip Cap (Picture D). The syringe with suspension for injection should be visually inspected prior to administration. In the event of any foreign particulate matter, leakage, premature activation of the plunger or faulty tip seal, discard the pre-filled syringe.

Picture A: Luer Lock Syringe with Rigid Tip Cap

Instructions for use of Safety Needle with Luer Lock pre-filled syringe:

Follow Step 1 and 2 above to prepare the Luer Lock syringe and needle for attachment.

Picture D: Luer Lock Syringe with Soft Tip Cap

The syringe is intended for single use only and must not be reused. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Aventis Pharma Limited

410 Thames Valley Park Drive

Reading

Berkshire

RG6 1PT

UK

Or trading as:

Sanofi Pasteur

410 Thames Valley Park Drive

Reading

Berkshire

RG6 1PT

UK